P.049: EFFECTS OF INHIBITION OF NITRIC OXIDE SYNTHASE ON THE PERIPHERAL ARTERIAL WAVEFORM RESPONSE TO EXERCISE

S.M. Munir*, B. Jiang, A. Guilcher, S. Brett, S. Redwood, P.J. Chowienczyk

To cite this article: S.M. Munir*, B. Jiang, A. Guilcher, S. Brett, S. Redwood, P.J. Chowienczyk (2006) P.049: EFFECTS OF INHIBITION OF NITRIC OXIDE SYNTHASE ON THE PERIPHERAL ARTERIAL WAVEFORM RESPONSE TO EXERCISE, Artery Research 1:S1, S39–S39, DOI: https://doi.org/10.1016/S1872-9312(07)70072-8

To link to this article: https://doi.org/10.1016/S1872-9312(07)70072-8

Published online: 21 December 2019
**FUNCTION IN PATIENTS WITH TYPE 2 DIABETES ON INSULIN**

Evaluating the effects of pacing and nitroglycerin (NTG) on estimation of central systolic pressure from the peripheral pulse.

**Methods:** Patients undergoing coronary angioplasty (n = 11, aged 48 to 72 years) participated. A Millar SPC-845D or fluid filled catheter was placed in the aortic root and a pacing wire in the right atrium. Peripheral digital arterial waveforms (Finometer) and aortic waveforms were obtained at baseline, during pacing at 20 bpm above resting heart rate and during adenosine infusion (10 and 100 μg/min, i.v.).

**Results:** Pacing and NTG produced marked changes in central and peripheral waveforms, reducing central augmentation index from 40.4 ± 2.6 to 22.6 ± 6.8% and from 40.4 ± 6.2 to 12.7 ± 7.0% for pacing and NTG 100 ng/min respectively (each P < 0.01). At baseline and during all interventions, there was a close correlation between central systolic blood pressure and absolute finger systolic pressure at the point of late systolic augmentation (R = 0.95, P < 0.0001). The mean difference between measured central aortic systolic BP and that estimated from digital pressure was 2.2 mmHg (6.2 mmHg).

**Conclusions:** These data suggest that central systolic blood pressure can be estimated directly from non-invasive finger pressure waveforms even during interventions such as pacing and NTG that produce a marked change in pressure waveforms.

---

**EFFECTS OF INHIBITION OF NITRIC OXIDE SYNTHASE ON THE PERIPHERAL ARTERIAL WAVEFORM RESPONSE TO EXERCISE**

S.M. Munir*, B. Jiang, A. Gulicher, S. Brett, S. Redwood, P.J. Chowienczyk

**Cardiovascular Division, King's College School of Medicine, London, United Kingdom**

**Introduction:** Exercise reduces systolic augmentation in the peripheral pulse wave, an effect similar to that produced by the nitric oxide (NO) donor nitroglycerin (NTG). The changes produced by exercise persist into the recovery period for ~30 min. The aim of this study was to investigate if the exercise-induced changes are dependent on endothelium-derived NO. We used the NO synthase inhibitor Nω-monomethyl-L-arginine (L-NMMA) to test this.

**Methods:** Healthy volunteers (n = 10, 5 female, aged 19 to 33 years) participated in a 2-phase randomised controlled cross-over study. L-NMMA (6 mg/kg i.v. over 5 min) and saline placebo were given immediately before exercise on two occasions separated by at least 5 days. Mean arterial blood pressure (MAP by Finapres), radial augmentation index (RAIx by SphynxCor) and cardiac output (innocor) measurements were made at baseline, during infusion of L-NMMA/saline immediately before exercise, during exercise (except for radial artery measurements) and during recovery. Peripheral vascular resistance (PVR) was calculated from MAP and cardiac output. During exercise, workload increased from 25 W to 150 W by increments of 25 W at 2 min intervals.

**Results:** Before exercise, L-NMMA increased mean arterial blood pressure (85.1 ± 3.8 vs. 101.2 ± 4.3 mmHg, P < 0.01), peripheral vascular resistance (16.4 ± 0.7 vs. 24.7 ± 1.7 mmHg/ml/min, P < 0.01) and RAIx (50.2 ± 4.5 vs. 70.2 ± 6.5%, P < 0.01) and decreased heart rate (65.6 ± 5.7 vs. 49.1 ± 2.8 bpm, P < 0.01) and after exercise, heart rate and PVR were similar, and RAIx fell after L-NMMA and saline. However, L-NMMA attenuated the exercise-induced fall in RAIx so that RAIx was higher after L-NMMA compared to saline at 15 min in recovery (49.5 ± 5.3 vs. 36.0 ± 4.4%, P < 0.02).

**Conclusion:** These data suggest that, although endothelium derived NO has little effect in regulating PVR during/after exercise, it may have a role in mediating exercise-induced changes in the pulse waveform.

---

**EVALUATION OF ENDOTHELIAL FUNCTION WITH NON-INVASIVE METHODS IN DIFFERENT CARDIOVASCULAR DISEASES**

J. Nemec†, J. Egeris†, J. Borovende‡, E. Kolassiváry, E. Finta, K. Farkas, I. Kiss. Szent Imre Teaching Hospital, Department of Angiology and Nephrology, Budapest, Hungary

The aim of our study was to evaluate microvascular reactivity and arterial stiffness with non-invasive methods in patients with different cardiovascular risk factors. Following blood pressure measurement, skin microcirculation was studied with laser Doppler flowmetry (Periflux 5001). The effect of local heating (LH; 44°C, 1 min) and the postocclusive reactive hyperaemia (PORH; 220 mmHg, 3 min) were measured. Arterial stiffness was evaluated with the newly developed TensoClinic Arteriograph instrument which calculates the pulse wave velocity (PWV, m/s) and augmentation index (AIX, %). Healthy controls (CONT, n = 13), patients with essential hypertension (EH, n = 13), with essential hypertension and peripheral artery disease (EH-PAD, n = 22), and essential hypertension and 2-type diabetes mellitus (EH+DM, n = 25) were measured. Pulse pressure (PP) was higher in EH-PAD (62.6 ± 3.2 mmHg, p < 0.05) and EH+DM (67.6 ± 3.1 mmHg, p < 0.001) groups compared with CONT (52.5 ± 3.4 mmHg). AIX, PWV and the PORH were significantly different in healthy controls (-62.1, 7.01% m/s, 393.77%, resp.) compared to the patient groups. These parameters were significantly different in the EH (-34.2%, 7.91 m/s, 292.77%), EH-PAD (651 ± 533%) and EH+DM (453 ± 45%) compared with the CONT (1049 ± 133%). Significant correlation was found between the PORH and Aix (r = 0.54, p = 0.001) and PP and Aix (r = 0.42, p = 0.05). Using these non-invasive methods there is a growing possibility to diagnose endothelial dysfunction in patients with different cardiovascular diseases. Prospective studies are needed to evaluate the prognostic value and the utility in therapy follow-up of these methods.

---

**BLOOD PRESSURE AND LARGE ARTERIAL ELASTIC PROPERTIES. BENEFIT OF BETAXOLOL IN HYPERTENSION**

F.T. Ageye, T.Y.A. Ortolva*, B.D. Kulev, O.N. Baldina. Cardiology Research Center, Moscow, Russia

**Background and Aim:** Large artery damage is a major contributory factor to cardiovascular morbidity and mortality of patients with hypertension. As shown ASCOT and other study, beta-blockers appear to be less effective than other drugs in improving outcome in hypertensive patients, and a potential explanation may be that beta-blockers are less effective in reducing arterial stiffness. However, the aim of this study was to prove otherwise while assessing the direct effect of cardioprotective beta-adrenoceptor blockers betaxolol (Lokren) on arterial distensibility in patients with mild, moderate and severe hypertension.

**Materials and Methods:** 50 hypertensive patients (mean age 54.7 ± 14.3 years, 28 male, 32 female) received betaxolol in individual titrated doses 10-40 mg (mean dose 14.7 ± 4.6 mg) daily for 3 months. The examination comprised routine tests, ECG, blood glucose, total cholesterol, triglycerides. The assessment of arterial stiffness was done by way of measuring brachial-ankle pulse wave velocity (baPWV). Systemic arterial compliance was estimated through brachial Augmentation Index (AI), Endothelial function was calculated based on flow-mediated dilation (FMD) parameters.

**Results:** The treatment produced a significant reduction in systolic (by 3.4 ± 5.7%) and diastolic BP (by 1.3 ± 3.3 mmHg). There were no significant changes at 6 months in any variable except for diastolic blood pressure that dropped from 79.7 ± 7 to 72.1 ± 12 mmHg (p < 0.05). In groups A and B, no significant reductions in glycated hemoglobin (from 8.3 ± 0.1 to 7.8 ± 1.0%, P = 0.0005) and fasting plasma glucose (from 104 ± 164 to 144 ± 61 mg/dl, P < 0.05) was observed at 6 months, while FMD significantly improved from (1.3 ± 1.46 to 2.98 ± 1.80%, P < 0.005).

**Conclusion:** In betaxolol-treated type 2 diabetic patients, treatment with rosiglitazone for 6 months has a beneficial effect on glycemic control and endothelial function.

---

**INSULIN-SENSITIVE ROSIGLITAZONE IMPROVES ENDOTHELIAL FUNCTION IN PATIENTS WITH TYPE 2 DIABETES ON INSULIN**

K. Papathanassiou*, K.K. Naka†, N. Kazakos‡, K. Pappas‡, K. Liveris‡, N. Kazakos

**Department of Endocrinology, Matiokista General Hospital, Ioannina, Greece, †Department of Endocrinology, University Hospital of Ioannina, Ioannina, Greece**

**Aim:** Thiazolidinediones (TZDs) are insulin sensitizers used to improve glycaemic control in diabetic patients. TZDs have also been reported to improve endothelial function in obese patients with insulin resistance and in diabetic patients on oral treatment. However, little is known about the vascular effects of TZDs in patients with type 2 diabetes treated with insulin.

**Methods:** Thirty-one diabetic patients without known coronary artery, cerebrovascular or peripheral arterial disease, who were already on an insulin regime, were randomized to 2 groups; no treatment was added to group A (n = 14), while rosiglitazone (45 mg/day) was added to group B (n = 17) for 6 months. Flow-mediated dilation (FMD) in the brachial artery was assessed in all patients, at baseline and at follow-up.

**Results:** At baseline, the 2 groups did not differ in age (mean ± SD, 67.3 ± 6.4 vs 64.7 ± 7.6 years, respectively, p = ns), or any measured variable. In group A there were no significant changes at 6 months in any variable except for diastolic blood pressure that dropped from 79.7 ± 7 to 72.1 ± 12 mmHg (p < 0.05). In groups A and B, no significant reductions in glycated hemoglobin (from 8.3 ± 0.1 to 7.8 ± 1.0%, P = 0.0005) and fasting plasma glucose (from 104 ± 164 to 144 ± 61 mg/dl, P < 0.05) was observed at 6 months, while FMD significantly improved from (1.3 ± 1.46 to 2.98 ± 1.80%, P < 0.005).

**Conclusion:** In insulin-treated type 2 diabetic patients, treatment with rosiglitazone for 6 months has a beneficial effect on glycemic control and endothelial function.